Novo Total Current Liabilities from 2010 to 2024
| NVO Stock | USD 106.13 1.57 1.50% |
Total Current Liabilities | First Reported 1985-12-31 | Previous Quarter 187.9 B | Current Value 208.4 B | Quarterly Volatility 45.5 B |
Check Novo Nordisk financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Novo Nordisk's main balance sheet or income statement drivers, such as Depreciation And Amortization of 9.9 B, Interest Expense of 429.4 M or Selling General Administrative of 6.5 B, as well as many indicators such as Price To Sales Ratio of 14.15, Dividend Yield of 0.0154 or PTB Ratio of 30.84. Novo financial statements analysis is a perfect complement when working with Novo Nordisk Valuation or Volatility modules.
Novo | Total Current Liabilities |
Latest Novo Nordisk's Total Current Liabilities Growth Pattern
Below is the plot of the Total Current Liabilities of Novo Nordisk AS over the last few years. Total Current Liabilities is an item on Novo Nordisk balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Novo Nordisk AS are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. It is the total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations. Novo Nordisk's Total Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Novo Nordisk's overall financial position and show how it may be relating to other accounts over time.
| Total Current Liabilities | 10 Years Trend |
|
Total Current Liabilities |
| Timeline |
Novo Total Current Liabilities Regression Statistics
| Arithmetic Mean | 65,931,167,547 | |
| Geometric Mean | 43,931,457,597 | |
| Coefficient Of Variation | 81.02 | |
| Mean Deviation | 41,182,121,636 | |
| Median | 47,436,000,000 | |
| Standard Deviation | 53,420,449,001 | |
| Sample Variance | 2853744371.5T | |
| Range | 176.5B | |
| R-Value | 0.92 | |
| Mean Square Error | 468167064.5T | |
| R-Squared | 0.85 | |
| Slope | 10,997,767,527 | |
| Total Sum of Squares | 39952421200.9T |
Novo Total Current Liabilities History
About Novo Nordisk Financial Statements
Novo Nordisk investors utilize fundamental indicators, such as Total Current Liabilities, to predict how Novo Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Total Current Liabilities | 169.7 B | 178.1 B |
Pair Trading with Novo Nordisk
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Novo Nordisk position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Novo Nordisk will appreciate offsetting losses from the drop in the long position's value.Moving together with Novo Stock
| 0.87 | VALN | Valneva SE ADR | PairCorr |
| 0.91 | FDMT | 4D Molecular Therapeutics | PairCorr |
| 0.87 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.83 | LLY | Eli Lilly Sell-off Trend | PairCorr |
Moving against Novo Stock
| 0.92 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.85 | GILD | Gilead Sciences | PairCorr |
| 0.81 | NAMS | NewAmsterdam Pharma | PairCorr |
| 0.62 | LPCN | Lipocine | PairCorr |
| 0.55 | PMVP | Pmv Pharmaceuticals | PairCorr |
The ability to find closely correlated positions to Novo Nordisk could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Novo Nordisk when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Novo Nordisk - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Novo Nordisk AS to buy it.
The correlation of Novo Nordisk is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Novo Nordisk moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Novo Nordisk AS moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Novo Nordisk can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Novo Nordisk Correlation against competitors. You can also try the Stocks Directory module to find actively traded stocks across global markets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novo Nordisk. If investors know Novo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novo Nordisk listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.224 | Dividend Share 9.9 | Earnings Share 2.99 | Revenue Per Share 60.698 | Quarterly Revenue Growth 0.214 |
The market value of Novo Nordisk AS is measured differently than its book value, which is the value of Novo that is recorded on the company's balance sheet. Investors also form their own opinion of Novo Nordisk's value that differs from its market value or its book value, called intrinsic value, which is Novo Nordisk's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novo Nordisk's market value can be influenced by many factors that don't directly affect Novo Nordisk's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novo Nordisk's value and its price as these two are different measures arrived at by different means. Investors typically determine if Novo Nordisk is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novo Nordisk's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.